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β-lactam antibiotics are the most 
commonly prescribed antimicrobials. This 
class of  antibiotics includes penicillin, 
cephalosporin, and carbapenem.  In these 
drugs, there is a strained four membered 
ring with an amide bond known as 
a β-lactam ring that is important for 
the reactivity of  β-lactams. β-lactam 
antibiotics act by inhibiting  penicillin 
binding proteins (PBPs), an enzyme native 
to bacteria, and disrupt biosynthesis of  
the bacterial cell wall leading to cell lysis 
and death. Unfortunately, bacteria have 
developed mechanisms that eliminate the 
β-lactam’s potency, subsequently leading 
to resistance. 
Among the mechanisms bacteria 
employ for resistance, the expression of  
β-lactamases is the most common. These 
enzymes confer resistance to β-lactam 
antibiotics by hydrolyzing the lactam ring 
through a two-step acylation-deacylation 
mechanism. Once the β-lactam ring is 
hydrolyzed, it is inactivated. There are 
four classes of  β-lactamases: A, B, C, 
and D. Classes A, C, and D employ a 
serine based mechanism to hydrolyze the 
β-lactam ring, while class B β-lactamases 
are metalloproteins that require zinc 
for their activity. Although all classes of  
β-lactamases are of  clinical importance, 
class D β-lactamases, also known as 
OXAs, are the least understood. A 
particular subset of  the class D enzymes 
is of  particular concern: the carbapenem-
hydrolyzing class D β-lactamases of  
which OXA-24 is a member. In OXA-24 
mechanism, a carboxylated lysine is used 
to hydrolyze carbapenems, which is a 
troubling trend, as carbapenems are the 
newest antibiotics and often used as a last 
resort. 
In an effort to combat antibiotic 
resistance against β-lactams, combination 
therapies consisting of  a β-lactam 
antibiotic with a β-lactamase inhibitor 
have been employed. However, current 
β-lactamase inhibitors also contain a 
β-lactam ring. Due to this structural 
similarity to β-lactam antibiotics, 
inhibitors are also susceptible to existing 
resistance mechanisms of  bacteria. 
Currently, there are no commercially 
available inhibitors for class D 
β-lactamases. The main objective of  our 
research is studying class D β-lactamases 
to discover novel inhibitors that are 
structurally different from β-lactam 
antibiotics. In this effort, creating novel 
inhibitors would serve as an advantage 
against bacteria by circumventing 
the traditional β-lactam resistance 
mechanisms. 
To discover a novel inhibitor for 
OXA-24, we took a structure-based 
approach to optimize an identified lead 
fragment. In the beginning stages, a 
molecular docking program, DOCK, 
identified a non-covalent fragment 
(Fragment #5) showing some signs of  
inhibition against OXA-24 with a Ki 
of  3.53 mM. For optimizing this lead, 
commercially available analogs were 
ordered and tested for inhibition against 
OXA-24. So far, nine analog compounds 
have been experimentally tested against 
OXA-24. Of  the nine analogs, one 
inhibits with a Ki of  0.100 mM, showing 
improved binding affinity of  35 fold 
over the lead. As a continuing focus, we 
will look at further optimizing this series 
of  novel inhibitors to improve binding, 
ultimately working towards developing a 
clinically-relevant novel inhibitor.
